Shots:

• The first patient has been enrolled at the first site in P-II MSC-COV-202BR efficacy study evaluates COVI-MSC vs PBO in 100 patients with COVID-19-induced ARD or ARDS in Brazil
• The primary objective of the study is to evaluate the efficacy of COVI-MSCs in patients with COVID-19-induced ARD or ARDS
• Additionally- the company plans to start the enrollment for two additional P-III studies with COVI-MSC across multiple sites in the US & Brazil

| Ref: Sorrento | Image: City Biz